Efficacy and Safety of Simeprevir Plus Ribavirin/Pegylated-Interferon for the Treatment of Hepatitis C Virus Genotype 1: A Meta Analysis / 中国药学杂志

ABSTRACT

OBJECTIVE: To assess efficacy and safety of simeprevir-based therapy for the treatment of hepatitis C virus genotype 1. METHODS: We searched Pubmed, EMBASE, the Cochrane Library, highwire, CBM, CNKI, Wanfang, VIP Database and literature from some relative paper based magazines also be retrieved. Randomised controlled trials(RCTs)of examining simeprevir plus ribavirin(RBV) and pegylated-interferon(peg-IFN) among adults with chronic HCV infection were included.Select the RCTs according to the inclusion criterion, then appraise them critiically by Cochrane handbook. All outcomes were pooled by the RevMan5.2 software of Cochrane Collaboration. Data were extracted on virological responses including sustained virological response at post-treatment week 12(SVR12), SVR24, serious adverse event(SAE),treat-ment discontinuation due to an adverse event(TDAE). RESULTS: Eight RCTs were finally included involving 2 758 patients who were treated with simeprevir, RBV and peg-IFN. The RESULTS of Meta-analysis showed that SVR12 rates was[OR=3.92,95%CI(2.86,5.39), P<0.000 01], SVR24 rates was[12 weekOR=3.79,95%CI(2.86,5.01), P<0.000 01], [24 weekOR=4.12,95%CI(2.69,6.30), P<0.000 01], SAE rates was[12 weekOR=0.67,95%CI(0.47,0.95),P=0.02], TDAE rates was[12 weekOR=0.85, 95%CI(0.54, 1.33), P=0.48],[24 weekOR=0.82,95%CI(0.42,1.60), P=0.55]. CONCLUSION: Evidence shows that, simeprevir-based treatment(simeprevir plus ribavirin and pegylated-interferon)for treating genotype 1 chronic HCV infection is better than PR treatment in SVR12 rates,SVR24 rates and SAE rates(course of treatment is 12 weeks). However, they are alike in TDAE rates.